Abliva AB NEVPF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.02
- Bid/Ask
- $0.05 / $0.15
- Market Cap
- $10.56 Mil
- Volume/Avg
- 204 / 3,602
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 817.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.abliva.com
Valuation
|
Metric
|
NEVPF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.49 |
Price/Sales | 817.62 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NEVPF
|
|---|---|
Quick Ratio | 3.59 |
Current Ratio | 3.80 |
Interest Coverage | −1,269.92 |
Quick Ratio
NEVPF
Profitability
|
Metric
|
NEVPF
|
|---|---|
Return on Assets (Normalized) | −63.18% |
Return on Equity (Normalized) | −70.54% |
Return on Invested Capital (Normalized) | −71.35% |
Return on Assets
NEVPF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jpwccjrjr | Lrnk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ytczcwjtx | Bjznv | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jwbzmpb | Nqxbcd | $99.5 Bil | |
MRNA
| Moderna Inc | Hbncnrn | Gpbq | $38.8 Bil | |
ARGX
| argenx SE ADR | Bnfqprd | Kbsyh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tvbztftz | Pgyfc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wwxlfczjx | Vgckxnv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yybvszz | Pkmlncr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kjcxljkqh | Vsfbzt | $12.5 Bil | |
INCY
| Incyte Corp | Ttvfjdkn | Xrynt | $11.6 Bil |